Medical Versus Surgical Management of Prolactinomas

Neurosurgery Clinics of North America

Volumn 23, Issue 4, 2012, Pages 669-678

  Oh, Michael C ^a   Kunwar, Sandeep ^a   Blevins, Lewis ^a   Aghi, Manish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bromocriptine; Cabergoline; Dopamine agonist; Pituitary adenoma; Prolactinomas; Transsphenoidal surgery

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PROLACTIN; QUINAGOLIDE; TEMOZOLOMIDE;

AMENORRHEA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPIC SURGERY; GAMMA KNIFE RADIOSURGERY; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MICROSCOPIC SURGERY; NAUSEA; NONFUNCTIONING PITUITARY ADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC RADIOSURGERY; SURGICAL APPROACH; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PITUITARY NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROLACTINOMA; RADIOSURGERY;

EID: 84867125293     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.06.010     Document Type: Review

References (57)

1. Monson J.P. The epidemiology of endocrine tumours. Endocr Relat Cancer 2000, 7(1):29-36.
2. CBTRUS. 2009-2010 CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. 2010. Available at: Accessed April 4, 2010. http://www.cbtrus.org.
3. DeLellis R.A., Lloyd R.V., Heitz P.U., et al. World Health Organization classification of tumours: tumours of endocrine organs 2004, IARC, Lyon (France).
4. Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009, 23(5):575-596.
5. Gillam M.P., Molitch M.E., Lombardi G., et al. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27(5):485-534.
6. Fainstein Day P., Guitelman M., Artese R., et al. Retrospective multicentric study of pituitary incidentalomas. Pituitary 2004, 7(3):145-148.
7. Daly A.F., Burlacu M.C., Livadariu E., et al. The epidemiology and management of pituitary incidentalomas. Horm Res 2007, 68(Suppl 5):195-198.
8. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101(3):613-619.
9. Losa M., Mortini P., Barzaghi R., et al. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002, 87(7):3180-3186.
10. Tyrrell J.B., Lamborn K.R., Hannegan L.T., et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999, 44(2):254-261. [discussion: 261-3].
11. Molitch M.E., Elton R.L., Blackwell R.E., et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985, 60(4):698-705.
12. Casanueva F.F., Molitch M.E., Schlechte J.A., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006, 65(2):265-273.
13. Daly A.F., Rixhon M., Adam C., et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91(12):4769-4775.
14. Ferrante E., Ferraroni M., Castrignanò T., et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 2006, 155(6):823-829.
15. Kim S.H., Lee K.C. Cranial nerve palsies accompanying pituitary tumour. J Clin Neurosci 2007, 14(12):1158-1162.
16. Klijn J.G., Lamberts S.W., de Jong F.H., et al. The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension of tumour. Clin Endocrinol (Oxf) 1980, 12(4):341-355.
17. Schlechte J., Dolan K., Sherman B., et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989, 68(2):412-418.
18. Bassetti M., Spada A., Pezzo G., et al. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab 1984, 58(2):268-273.
19. Tindall G.T., Kovacs K., Horvath E., et al. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982, 55(6):1178-1183.
20. Molitch M.E. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002, 5(2):55-65.
21. Webster J., Piscitelli G., Polli A., et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331(14):904-909.
22. Pascal-Vigneron V., Weryha G., Bosc M., et al. Presse Med 1995, 24(16):753-757. [in French].
23. Ono M., Miki N., Kawamata T., et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008, 93(12):4721-4727.
24. Colao A., Pivonello R., Di Somma C., et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 2009, 10(2):111-123.
25. Van Camp G., Flamez A., Cosyns B., et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363(9416):1179-1183.
26. Colao A., di Sarno A., Pivonello R., et al. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002, 11(6):787-800.
27. Molitch M.E. Dopamine resistance of prolactinomas. Pituitary 2003, 6(1):19-27.
28. Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 2005, 8(1):43-52.
29. Oh M.C., Aghi M.K. Dopamine agonist-resistant prolactinomas. J Neurosurg 2011, 114(5):1369-1379.
30. Brue T., Pellegrini I., et al. Prolactinomas and resistance to dopamine agonists. Horm Res 1992, 38(1-2):84-89.
31. Morange I., Barlier A., Pellegrini I., et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996, 135(4):413-420.
32. Pellegrini I., Rasolonjanahary R., Gunz G., et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989, 69(3):500-509.
33. Delgrange E., Daems T., Verhelst J., et al. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009, 160(5):747-752.
34. Di Sarno A., Landi M.L., Cappabianca P., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001, 86(11):5256-5261.
35. Hagen C., Schroeder H.D., Hansen S., et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009, 161(4):631-637.
36. Neff L.M., Weil M., Cole A., et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007, 10(1):81-86.
37. Sheehan J., Rainey J., Nguyen J., et al. Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 2011, 114(2):354-358.
38. Castinetti F., Regis J., Dufour H., et al. Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol 2009, 6(4):214-223.
39. Hamilton D.K., Vance M.L., Boulos P.T., et al. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005, 8(1):53-60.
40. Faria M.A., Tindall G.T. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg 1982, 56(1):33-43.
41. Hardy J., Beauregard H., Robert F., et al. Prolactin-secreting pituitary adenomas: transsphenoidal microsurgical treatment. Clin Neurosurg 1980, 27:38-47.
42. Thomson J.A., Davies D.L., McLaren E.H., et al. Ten year follow up of microprolactinoma treated by transsphenoidal surgery. BMJ 1994, 309(6966):1409-1410.
43. Abe T., Matsumoto K., Kuwazawa J., et al. Headache associated with pituitary adenomas. Headache 1998, 38(10):782-786.
44. Scheithauer B.W., Jaap A.J., Horvath E., et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 2000, 47(3):723-729. [discussion: 729-30].
45. Forsyth P.A., Posner J.B. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993, 43(9):1678-1683.
46. Jensen R., Stovner L.J. Epidemiology and comorbidity of headache. Lancet Neurol 2008, 7(4):354-361.
47. Fleseriu M., Yedinak C., Campbell C., et al. Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg 2009, 110(2):354-358.
48. Buchfelder M., Schlaffer S. Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab 2009, 23(5):677-692.
49. Kitano M., Taneda M., Shimono T., et al. Extended transsphenoidal approach for surgical management of pituitary adenomas invading the cavernous sinus. J Neurosurg 2008, 108(1):26-36.
50. Higgins T.S., Courtemanche C., Karakla D., et al. Analysis of transnasal endoscopic versus transseptal microscopic approach for excision of pituitary tumors. Am J Rhinol 2008, 22(6):649-652.
51. Tabaee A., Anand V.K., Barrón Y., et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg 2009, 111(3):545-554.
52. Sun D.Q., Cheng J.J., Frazier J.L., et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev 2011, 34:181-189.
53. Kokubo M., Sasai K., Shibamoto Y., et al. Long-term results of radiation therapy for pituitary adenoma. J Neurooncol 2000, 47(1):79-84.
54. Zierhut D., Flentje M., Adolph J., et al. External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys 1995, 33(2):307-314.
55. Sheehan J.P., Jagannathan J., Pouratian N., et al. Stereotactic radiosurgery for pituitary adenomas: a review of the literature and our experience. Front Horm Res 2006, 34:185-205.
56. Sheehan J.P., Niranjan A., Sheehan J.M., et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005, 102(4):678-691.
57. Tanaka S., Link M.J., Brown P.D., et al. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 2010, 74(1):147-152.